Skip to content
News Center
About Us Careers News Center Contact Us Legal Doing Business with Illumina Investors Illumina for Startups Customer Engagement Center

Corporate, Community, Cancer research, Complex disease genomics, Drug discovery & development, Oncology, Reproductive health, Genetic & rare diseases

Video: Francis deSouza Speaks at the 16th Annual Precision Medicine World Conference

A discussion about the current and future state of genomics with Twist Bioscience’s Emily Leproust

Francis deSouza Speaks at the 16th Annual Precision Medicine World Conference
February 13, 2019

Recently, Francis de Souza, President and CEO of Illumina, Inc. spoke at the Personalized Medicine World Conference in Silicon Valley to discuss the adoption of clinical genomics, the future of genomics and how Illumina is helping advance science, transform medicine, and impact lives. He was interviewed by Emily Leproust, Ph.D., CEO of Twist Biosciences, who was an early pioneer in high-throughput synthesis and DNA sequencing.

Genomics is going to have the most profound impact of anything I've seen in my lifetime.

Francis deSouza
*Photo courtesy of Precision Medicine World Conference
Previous Article
Next Article

Recent articles

At Michigan Medicine, WGS becomes the backbone of molecular pathology
At Michigan Medicine, WGS becomes the backbone of molecular pathology
Geraldine Bliss wants parents to ask, “Could it be genetic?”
Geraldine Bliss wants parents to ask, “Could it be genetic?”
Illumina gets behind the wheel to drive greater results
Video: Illumina gets behind the wheel to drive greater results
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.